The GH/IGF-1 axis and heart failure

Current Cardiology Reviews

Volumn 5, Issue 3, 2009, Pages 203-215

  Castellano, Graziella ^a   Affuso, Flora ^a   Di Conza, Pasquale ^a   Fazio, Serafino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acromegaly; Chronic heart failure; GH deficiency; GH IGF 1 axis

Indexed keywords

ALPHA ACTIN; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL L TYPE; GROWTH HORMONE; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOSIN LIGHT CHAIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TROPONIN I;

ACROMEGALY; APOPTOSIS; ARTERY INTIMA; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; FIBROBLAST; GENE ACTIVATION; GROWTH HORMONE DEFICIENCY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HORMONE ACTION; HORMONE SENSITIVITY; HUMAN; IMMUNOMODULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; UPREGULATION; VASODILATATION;

EID: 70449644857     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340309788970306     Document Type: Review

References (219)

1. Duello TM, Halmi NS. Ultrastructural-immunocytochemical localization of growth hormone and prolactin in human pituitaries. J Clin Endocrinol Metab 1979; 49: 189-196 (Pubitemid 9241260)
2. Thorner MO, Vance ML, Horvath E, Kovacs K. In: Wilson JD, Foster DW Ed, Textbook of Endocrinology. The anterior pituitary. Philadelphia, WB Saunders Co, 1992; pp. 221-310.
3. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology 1984; 115: 1952-1957.
4. Plotsky PM, Vale W. Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophyseal-portal circulation of the rat. Science 1985; 230: 461-463 (Pubitemid 16192562)
5. Arce V, Lima L, Lois N, et al. Role of central dopaminergic pathways in the neural control of growth hormone secretion in normal men: studies with metoclopramide. Neuroendocrinology 1991; 53: 143-149
6. Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982; 218: 585-589
7. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-79
8. Casanueva FF. Physiology of growth hormone secretion and action. Endocrinol Metab Clin North Am 1992; 21: 483-515.
9. Laron Z. Growth hormone secretagogues: clinical, experimental and therapeutic potential. Drugs 1995; 50: 595-601.
10. Gomberg-Maitland M, Frishman WH. Recombinant growth hormone: a new cardiovascular drug therapy. Am Heart J 1996; 132: 1244-1262 (Pubitemid 127738609)
11. Strobl JS, Thomas MJ. Human growth hormone. Pharmacol Rev 1995; 46: 1-34.
12. Tapanaienen P, Knip M. Evaluation of growth hormone secretion and treatment. Ann Med 1992; 24: 237-247
13. Dronby EC, Amburn K, Powmakn G. Circadian variation of basal growth hormone in man. J Clin Endocrin Metab 1983; 57: 524-528
14. Moller N, Jorgensen JOL, Abildgard N, Orskov L, Schmitz O, Christiansen JS. Effects of growth hormone on glucose metabolism. Horm Res 1991; 36: 32-35
15. Betherat J, Bluet-Pajt MT, Eppelbaun J. Neuroendocrine regulation of growth hormone. Eur J Endocrinol 1995; 132: 12-24.
16. Rudman D, Kutner MH, Rogers MC, Lubin MF, Fleming Ga, Bain RP. Impaired growth hormone secretion in the adult population. Relation to age and adiposity. J Clin Invest 1981; 67: 1361-1369 (Pubitemid 11099350)
17. Rudman D. Growth hormone, body composition and aging. J Am Geriatr Soc 1985; 33: 800-807 (Pubitemid 16183980)
18. Rudd BT. Growth hormone and the somatomedins: a historical perspective and current concepts. Ann Clin Biochem 1991; 28: 542-555
19. Mathews LS, Enberg B, Norstedt G. Regulation of rat growth hormone receptor gene expression. J Biol Chem 1989; 17: 9905-9910
20. Sotiropoulos A, Perrot-Applanat M, Dinerstein H, et al. Distinct cytoplasmatic regions of the growth hormone receptor are required for activation of JAK2, mitogen-activated protein kinase, and transcription. Endocrinology 1994; 135: 1289-1291
21. Underwood LE, Van Wyk JJ. In: Wilson JD, Foster DW Ed, Textbook of Endocrinology. Normal and aberrant growth. Philadelphia, WB Saunders Co. 1992; pp. 1079-1138
22. Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol 2004; 151: 93-101.
23. Froesch ER, Schnid C, Schwander J, Zapf J. Action of insulin-like growth factors. Annu Rev Physiol 1985; 47: 443-467
24. Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Action of growth hormone: current views. Acta Paediatr Scand 1988; 343: 12-18
25. Laron Z. Somatomedin, insulin, growth hormone and growth: a review. Isr J Med Sci 1982; 18: 823-829
26. Salmon WD, Daughaday H. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825-836
27. Daughaday WH, Karl IE, Karl MM. A failed assay opened a new door in growth hormone research. Endocrinology 1992; 130: 565-566
28. Murphy LJ, Bell GI, Friesen Hg. Growth hormone stimulates sequential induction of c-myc and insulin-like growth factor I expression in vivo. Endocrinology 1987; 120: 1806-1812 (Pubitemid 17069208)
29. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S.Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004; 114: 349-356 (Pubitemid 39071607)
30. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555-573
31. Fazio S, Palmieri EA, Biondi B, Cittadini A, Saccà L. The role of the GH-IGF-1 axis in the regulation of myocardial growth: from experimental model to human evidence. Eur J Endocrinol 2000; 142: 211-216 (Pubitemid 30176928)
32. Meyers DE, Cuneo RC. Controversies regarding the effects of growth hormone on the heart. Mayo Clin Proc 2003; 78: 1521-1526 (Pubitemid 37475635)
33. Svensson J, Tivesten A, Isgaard J. Growth hormone and the cardiovascular function. Minerva Endocrinol 2005; 30: 1-13.
34. Foncea R, Andersson M, Ketterman A, et al. Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes. J Biol Chem 1997; 272: 19115-19124 (Pubitemid 27337697)
35. Giordano R, Bonelli L, Marinazzo E, Ghigo E, Arvat E. Growth hormone treatment in human aging: benefit and risks. Hormones 2008; 7(2): 133-139
36. Takahashi S, Meites J. GH binding to liver in young and old female rats: relation to somatomedin-C secretion. Proc Soc Exp Biol Med 1987; 186: 229-233 (Pubitemid 18031359)
37. Xu X, Bennett SA, Ingram RL, Sonntag WE. Decreases in growth hormone receptor signal transduction contribute to the decline in insulin-like growth factor I gene expression with age. Endocrinology 1995; 136: 4551-4557
38. D'Costa AP, Xu X, Ingram RL, Sonntag WE. Insulin-like growth factor-1 stimulation of protein synthesis is attenuated in cerebral cortex of aging rats. Neuroscience 1995; 65: 805-813
39. Carvalho CR, Brenelli SL, Silva AC, et al. Effect of aging on insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of rats. Endocrinology 1996; 137:151-159
40. Xu X, Sonntag WE. Growth hormone-induced nuclear translocation of Stat-3 decreases with age: modulation by caloric restriction. Am J Physiol 1996; 271: E903-9.
41. Roupas P, Herington AC. Postreceptor signaling mechanisms for growth hormone. Trends Endocrinol Metab 1994; 5: 154-158 (Pubitemid 24178185)
42. Nitahara JA, Cheng W, Liu Y, et al. Intracellular calcium, DNase activity and myocyte apoptosis in aging Fischer 344 rats. J Mol Cell Cardiol 1998; 30: 519-535
43. Olivetti, G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res 1991; 68: 1560-1568
44. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-39.
45. Eghbali M, Robinson TF, Seifter S, Blumenfeld OO. Collagen accumulation in heart ventricles as a function of growth and aging. Cardiovasc Res 1989; 23: 723-729 (Pubitemid 19201477)
46. Rudman D, Kutner MH, Rogers CM, et al. Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 1981; 67:1361-1369 (Pubitemid 11099350)
47. Ghigo E, Goffi S, Nicolosi M, et al. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. J Clin Endocrinol Metab 1990; 71: 1481-1485 (Pubitemid 120032763)
48. Bichell DP, Kikuchi K, Rotwein P. Growth hormone rapidly activates insulin-like growth factor I gene transcription in vivo. Mol Endocrinol 1992; 6: 1899-1908
49. Parrado J, Bougria M, Ayala A, Castano A, Machado A. Effects of aging on the various steps of protein synthesis: fragmentation of elongation factor 2. Free Radic Biol Med 1999; 26: 362-370 (Pubitemid 29013468)
50. Huxley HE. The crossbridge mechanism of muscular contraction and its implications. J Exp Biol 1985; 115: 17-30.
51. Bouillon R. Growth hormone and bone. Horm Res 1991; 36: 49-55.
52. Davidson MB. Effects of growth hormone on carbohydrate and lipid metabolism. Endocri Rev 1987; 8: 115-131
53. Keller U, Miles JM. Growth hormone and lipids. Horm Res 1991; 36: 36-40.
54. Hjalmarson A, Isaksson O, Ahren K. Effects of growth hormone and insulin on amino acid transport in perfused heart rat. Am J Physiol 1969; 217: 1795-1802
55. Saloman F, Cuneo R, Sonksen PH. Growth hormone and protein metabolism. Horm Res 1991; 36: 41-43
56. Czernichow P. Growth hormone administration and carbohydrate metabolism. Horm Res 1993; 39: 102-103 (Pubitemid 23322351)
57. Grunfeld C, Sherman BM, Cavalieri RR. The acute effects of human growth hormone administration on thyroid function in normal man. J Clin Endocrinol Metab 1988; 67: 1111-1114 (Pubitemid 18277240)
58. Ho KY, Kelly JJ. Role of growth hormone in fluid homeostasis. Horm Res 1991; 36: 44-48
59. Moller J, Jorgensen JOL, Moller N, Hansen KW, Pedersen EB, Christiansen JS. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. J Clin Endocrinol Metab 1991; 72: 768-772 (Pubitemid 21921763)
60. Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996; 137: 1798-1803
61. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994; 45: 598-604. (Pubitemid 24065099)
62. Muniyappa R, Walsh MF, Rangi JS, et al. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci 1997; 61: 925-931 (Pubitemid 27339072)
63. Haylor J, Singh I, Nahas AM. Nitric oxide synthesis inhibitor prevents vasodilatation by insulin-like growth factor I. Kidney Int 1991; 39: 333-335
64. Hasdai D, Rizza RA, Holmes DR Jr, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. Hypertension 1998; 32: 228-234 (Pubitemid 28376477)
65. Caidahl K, Eden S, Bengtsson BA. Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf) 1994; 40: 393-400. (Pubitemid 24194635)
66. Fryburg D. NG- monomethyl-L-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF-1. Possible role of nitric oxide in muscle protein synthesis. J Clin Invest 1996; 97: 1319-1328 (Pubitemid 26085489)
67. Capaldo B, Guardasole V, Pardo F, et al. Abnormal vascular reactivity in growth hormone deficiency. Circulation 2001; 103: 520-524 (Pubitemid 32117701)
68. Napoli R, Guardasole V, Matarazzo M, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002; 39: 90-95 (Pubitemid 34059866)
69. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilation of peripheral conduit arterias in vivo. Circulation 1995; 92: 1314-1319
70. Badorff C, Dimmeler S. NO balance: regulation of the cytoskeleton in congestive heart failure by nitric oxide. Circulation 2003; 107: 1348-1349 (Pubitemid 36350729)
71. Standley PR, Zhang F, Zayas RM, et al. IGF-1 regulation of Na(+)- K(+)-ATPase in rat arterial smooth muscle. Am J Physiol 1997; 273; 113-121
72. Tivesten A, Barlind A, Caidahl K, et al. Growth hormone-induced blood pressure decrease is associated with increased mRNA levels of the vascular smooth muscle KATP channel. J Endocrinol 2004; 183: 195-202. (Pubitemid 40124656)
73. Fujita A, Kurachi A, Kurachi Y. Molecular aspects of ATP sensitive K+ channels in the cardiovascular system and K+ channel openers. Pharmacol Ther 2000; 85: 39-53.
74. Miki T, Suzuki M, Shibasaki T, et al. Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat Med 2002; 8: 466-472 (Pubitemid 34546748)
75. Butt RP, Laurent GJ, Bishop JE. Collagen deposition and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors. Eur J Cell Biol 1995; 68: 330-335
76. Bruel A, Oxlund. Biosynthetic growth hormone increase the collagen deposition rate in rat aorta and heart. Eur J Endocrinol 1995; 132: 195-199
77. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 1995; 92: 8031-8035
78. Li Q, Li B, Wang X, et al. Overexpression of insulin-like growth factor-I in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress and cardiac hypertrophy. J Clin Invest 1997; 100: 1991-1999 (Pubitemid 27459352)
79. Timsit J, Riou B, Bertherat J, et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 1990; 86: 507-515 (Pubitemid 20271883)
80. Cittadini A, Ishiguro Y, Stromer H, et al. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res 1998; 83: 50-59 (Pubitemid 28322099)
81. Mayoux E, Ventura-Clapier R, Timsit J, Behar-Cohen F, Hoffmann C, Mercadier JJ. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ Res 1993; 72: 57-64.
82. Ren J. Short-term administration of insulin-like growth factor (IGF-1) does not induce myocardial IGF-1 resistance. Growth Horm IGF Res 2002; 12: 162-168 (Pubitemid 35238090)
83. + current in ventricular myocytes from acromegalic rats. Am J Physiol 1991; 260: 935-942
84. 2+ channels by IGF-1. Biochem Biophys Res Commun 1998; 252: 151-155
85. Tajima M, Weinberg EO, Batunek J, et al. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 1999; 99: 127-134 (Pubitemid 29035967)
86. Houck Wv, Pan LC, Kribbs SB, et al. Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure. Circulation 1999; 100: 2003-2009 (Pubitemid 29529293)
87. Huchard H. Anatomie pathologique, lesions et trouble cardiovasculaires de l'acomegalie. J Praticiens 1895; 9: 249-251
88. Penney DG, Dunbar Jr JC, Baylerian MS. Cardiomegaly and hemodynamics in rats with a transplantable growth hormone-secreting tumor. Cardiovasc Res 1985; 19: 270-277
89. Rubin SA, Buttrick P, Malhotra A, Melmed S, Fishbein MC. Cardiac physiology, biochemistry and morphology in response to excess growth hormone in the rat. J Mol Cell Cardiol 1990; 22: 429-438 (Pubitemid 20195702)
90. Prysor-Jones RA, Jenkins JS. Effect of excessive secretion of growth hormone on tissues of the rat, with particular reference to the heart and skeletal muscle. J Endocrinol 1980; 85: 75-82.
91. Gilbert PL, Siegel RJ, Melmed S, Sherman CT, Fishbein MC. Cardiac morphology in rats with growth hormone-producing tumours. J Mol Cell Cardiol 1985; 17: 805-811 (Pubitemid 16247465)
92. Evans HM, Simpson HE, Li CH. The gigantism produced in normal rats by injection of pituitary growth hormone. Growth 1948; 12: 15-32.
93. Beznak M. The restoration of cardiac hypertrophy and blood pressure in hypophysectomized rats by large doses of lyophilized anterior pituitary and growth hormone. J Physiol (London) 1954; 124: 64-74.
94. Saccà L, Napoli R, Cittadini A. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol 2003; 59: 660-671 (Pubitemid 37492998)
95. Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen D. A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? Acta Med Scand 1988; 223: 337-343
96. Fazio S, Cittadini A, Biondi B, et al. Cardiovascular effects of short-terms growth hormone hypersecretion. J Clin Endocrinol Metab 2000; 85: 179-182 (Pubitemid 32268811)
97. Martins JB, Kerber RE, Sherman BM, Marcus ML, Ehrhardt JC. Cardiac function in acromegaly. Circulation 1977; 56: 863-869
98. Mather HM, Boyd MJ, Jenkins JS. Heart size and function in acromegaly. Br Heart J 1979; 41: 697-701.
99. Smallridge RC, Rajfer S, Davia J, Schaaf M. Acromegaly and the heart. An echocardiographic study. Am J Med 1979; 66: 22-27
100. Fazio S, Cittadini A, Sabatini D, et al. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. Eur Heart J 1993; 14: 26-33. (Pubitemid 23092635)
101. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly epidemiology, pathogenesis and management. Endocr Rev 2004; 25: 102-152 (Pubitemid 38269977)
102. Cittadini A, Berggren A, Longobardi S, et al. Supraphysiological doses of GH induce rapid changes in cardiac morphology and function. J Clin Endocrinol Metab 2002; 87: 1654-1659 (Pubitemid 34618502)
103. Fazio S, Cittadini A, Sabatini D, et al. Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J 1997; 18: 340-347
104. Bertoni PD, Morandi G. Impaired left ventricular diastolic in acromegaly: an echocardiographic study. Acta Cardiol 1985; 42: 1-10.
105. Morvan D, Komajda M, Grimaldi A, Turpin G, Grosgogeat Y. Cardiac hypertrophy and function in asymptomatic acromegaly. Eur Heart J 1991; 12: 666-672
106. Fazio S, Cittadini A, Cuocolo A, et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab 1994; 79: 441-446 (Pubitemid 24256532)
107. Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 1980; 100: 41-52.
108. Kahaly G, Stover C, Beyer J, Mohr-Kahaly S. Relation of endocrine and cardiac findings in acromegalics. J Endocrinol Invest 1992; 15: 13-18
109. Rossi L, Thiene G, Caregaro L, Giordano R, Lauro S. Dysrhythmias and sudden death in acromegalic heart disease. A clinicopathologic study. Chest 1977; 72: 495-498
110. Herrmann BL, Bruch C, Saller B, et al. Occurrence of left ventricular late potentials in patients active acromegaly. Clin Endocrinol 2001; 55: 201-207 (Pubitemid 32868584)
111. Colao A. Are patients with acromegaly at risk for dysrhythmias? Clin Endocrinol 2001; 55: 305-306
112. Van den Heuvel PACMB, Elbers HRJ, Plokker HWM, Bruschke VG. Myocardial involvement in acromegaly. Int J Cardiol 1984; 6: 550-555
113. Frustaci A, Chimenti C, Setoguchi M, et al. Cell death in acromegalic cardiomyopathy. Circulation 1999; 99: 1426-1434
114. Passa P, Masquet C, Cophignon J, Gourgon R, Bouvrain Y. Le coeur dans l'acromegalie. Etude hemodynamique. Arch Mal Coeur Vaiss 1973; 66: 1517-1523
115. Thuesen L, Christiansen JS, Sorensen KE, Jorgensen JOL, Orskov H, Henningsen P. Increased myocardial contractility following growth hormone administration in normal man. Dan Med Bull 1988; 35: 193-196
116. Losa M, von Werder K. In: Manelli F Ed. Growth hormone and the heart. The heart in acromegaly. Boston, Kluwer Academic Publishers, 2001; pp. 33-43.
117. Van Loon GR. Abnormal plasma catecholamine responses in acromegalics. J Clin Endocrinol Metab 1979; 48: 784-789
118. Sverrisdottir YB, Elam M, Herlitz H, Bengtsson BA, Johannsson G. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 1998; 83: 1881-1885 (Pubitemid 28496310)
119. Capaldo B, Lembo G, Rendina V, et al. Sympathetic deactivation by growth hormone in patients with dilated cardiomyopathy. Eur Heart J 1998; 19: 623-627 (Pubitemid 28224685)
120. Capaldo B, Lembo G, Rendina V, et al. Muscle sympathetic nerve activity in patients with acromegaly. J Clin Endocrinol Metab 2000; 85: 3203-3207 (Pubitemid 30944526)
121. Bondanelli M, Ambrosio MR, Franceschetti P, Margutti A, Trasforini G, Degli Uberti EC. Diurnal rhythm of plasma catecholamines in acromegaly. J Clin Endocrinol Metab 1999; 84: 2458-2467 (Pubitemid 30670880)
122. Moller J, Moller N, Frandsen E, Wolthers T, Jorgensen JO, Christiansen JS. Blockade of the renin-angiotensin-aldosterone system prevents growth hormone induced fluid retention in humans. Am J Physiol 1997; 272: 803-808
123. McCaa RE, Montalvo JM, McCaa CS. Role of growth hormone in the regulation of aldosterone biosynthesis. J Clin Endocrinol Metab 1978; 46: 247-253
124. Kalberg BE, Ottoson AM. Acromegaly and hypertension: role of the renin-angiotensin-aldosterone system. Acta Endocrinol 1982; 100: 581-587 (Pubitemid 12089236)
125. Leri A, Liu Y, Wang X, et al. Overexpression of insulin-like growth factor-I attenuates the myocytes renin-angiotensin system in transgenic mice. Circ Res 1999; 84: 752-762 (Pubitemid 29181482)
126. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
127. Andreassen M, Faber J, Vestergaard H, Kistorp C, Kristensen LØ. N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clin Endocrinol (Oxf) 2007; 66: 619-625 (Pubitemid 46699526)
128. Hanson MC, Kenneth AF, Alexander RW, De Lafontaine P. Induction of cardiac insulin-like growth factor I gene expression in pressure overload hypertrophy. Am J Med Sci 1993; 306: 69-74. (Pubitemid 23242727)
129. Isgaard J, Wahlander H, Adams MA, Friberg P. Increased expression of growth hormone receptor mRNA and insulin-like growth factor-I mRNA in volume-overloaded hearts. Hypertension 1994; 23: 884-888 (Pubitemid 24180831)
130. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1971; 39: 1-16.
131. Swearingen B, Barker FG, Katznelson L et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3419-3426 (Pubitemid 28500866)
132. Tokgozoglu SL, Erbas T, Aytemir K, Akalin S, Kes S, Oram E. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol 1994; 74: 1072-1074 (Pubitemid 124008476)
133. Pereira J, Rodriguez-Puras MJ, Leal-Cerro A, et al. Acromegalic cardiomyopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest 1991; 14: 17-23.
134. Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in patients with acromegaly. J Clin Endocrinol Metab 1993; 77: 790-793 (Pubitemid 23298668)
135. Colao A, Cuocolo A, Marzullo P, et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999; 84: 17-23. (Pubitemid 29036674)
136. Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001; 86: 1551-1557 (Pubitemid 32374902)
137. Baldelli R, Ferretti E, Jaffrain-Rea ML, et al. Cardiac effects of slow-release lanreotide, a slow release somatostatin analog, in acromegalic patients. J Clin Endocrin Metab 1999; 84: 527-532 (Pubitemid 29075679)
138. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol 2003; 58: 169-176 (Pubitemid 36194271)
139. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990; 113: 921-925
140. Ludens JH, Back RR, Williamson HE. Characteristics of the antinatriuretic action of growth hormone. Proc Soc Exp Biol Med 1969; 130: 1156-1158
141. Iida K, Koide Y, Matsuda M, et al. Follow-up study of the heart in acromegaly: pre- and post-operative evaluation. Jnp J Med 1990; 29: 22-26 (Pubitemid 20261881)
142. Lim MS, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992; 117: 719-726
143. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000; 86: 32-40.
144. Shahi M, Beshyah SA, Hackett D, Sharp PS, Johnston DG, Foale RA. Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality. Br Heart J 1992; 67: 92-96
145. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001; 54: 137-154
146. Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol 1999; 50: 1-15. (Pubitemid 29079362)
147. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803 (Pubitemid 20015573)
148. Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 1992; 37: 387-397
149. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999; 84: 453-457 (Pubitemid 29075668)
150. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992; 340: 1188-1192
151. Capaldo B, Patti L, Oliviero U, et al. Increased arterial intimamedia thickness in childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 1997; 82: 1378-1381 (Pubitemid 27200404)
152. Borson-Chazot F, Serusclat A, Kalfallah Y et al. Decrease in carotid intima-media thickness after 1 year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84: 1329-1333 (Pubitemid 30644395)
153. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor I induced nitric oxide production by endothelial cells. Kidney Int 1994; 45: 598-604. (Pubitemid 24065099)
154. Boger RH, Skamira C, Bode-Boger SM, Brabant C, Von Zur Muhlen A, Frolich JC. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency: a double blind placebo controlled study. J Clin Invest 1996; 98: 2706-2713 (Pubitemid 26427396)
155. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77: 1671-1677 (Pubitemid 24000933)
156. Merola B, Cittadini A, Colao A, et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993; 77: 1658-1661 (Pubitemid 24000930)
157. Cittadini A, Cuocolo A, Merola B, et al. Impaired cardiac performance in growth hormone deficient adults and its improvement after growth hormone replacement. Am J Physiol 1994; 267: 219-225
158. Longobardi S, Cuocolo A, Merola B, et al. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin Endocrinol 1998; 48: 137-143 (Pubitemid 28091042)
159. Thuesen L, Jorgensen JOL, Muller JR, et al. Short and long-term cardiovascular effects of growth hormone deficient adults. Clin Endocrinol 1994; 41: 615-650
160. Valcavi R, Gaddi O, Zini M, Iavicoli M, Mellino U, Portioli I. Cardiac performance and mass in adult with hypopituitarism: effects of one year of growth treatment. J Clin Endocrinol Metab 1995; 80: 659-666
161. Johannsson G, Bengtsson BA, Andersson B, Isgaard J, Caidahl K. Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults: preliminary data in a small group of patients. Clin Endocrinol 1996; 45: 305-314 (Pubitemid 26306699)
162. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991; 70: 688-694
163. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone deficient adults. II. Effects on exercise performance. J Appl Physiol 1991; 70: 695-770
164. Colao A, Cuocolo A, Di Somma C et al. Impaired cardiac performance in elderly patients with growth hormone deficiency. J Clin Endocrinol Metab 1999; 85: 3950-3955 (Pubitemid 30644179)
165. Colao A, Di Somma C, Cuocolo A et al. The severity of GH deficiency (GHD) correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab 2004; 89(12): 5998-6004. (Pubitemid 39628406)
166. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency. Circulation 2003; 108: 2648-2652 (Pubitemid 37466806)
167. Cuocolo A, Nicolai E, Colao A, et al. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism assessment with radionuclide angiography. Eur J Nucl Med 1996; 23: 390-394 (Pubitemid 26118324)
168. Colao A, Di Somma C, Cuocolo A, et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 2001; 86: 1874-1881.
169. Johannsson G, Albertsson-Wikland K, Bengtsson BA. Discontinuation of growth hormone (GH) treatment metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. J Clin Endocrinol Metab 1999; 84: 4516-4524 (Pubitemid 30677668)
170. Beshyah SA, Shahi M, Skinner E, Sharp P, Foale R, Johnston DG. Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. Eur J Endocrinol 1994; 130: 451-458 (Pubitemid 24165770)
171. Jorgensen JOL, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; 1: 1221-1225
172. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F Jr, Lombardi G. The cardiovascular risk of growth hormone-deficient adolescents. J Clin Endocrinol Metab 2002; 87: 3650-3655 (Pubitemid 34879507)
173. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo controlled trials. J Clin Endocrinol Metab 2004; 89: 2192-2199 (Pubitemid 38619852)
174. Chrisoulidou A, Beshyah SA, Rutherford O, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000; 85: 3762-3769
175. Colao A, Di Somma C, Rota F, et al. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab 2005; 90: 2056-2062
176. Colao A, Di Somma C, Cuocolo A, et al. Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a 2-year open, prospective study in young adult men and women with severe GH deficiency. J Clin Endocrinol Metab 2005; 90: 5146-5155 (Pubitemid 41262267)
177. Castagnino HE, Toranzos FA, Milei J, et al. Preservation of the myocardial collagen framework by human growth hormone in experimental infarctions and reduction in the incidence of ventricular aneurysms. Int J Cardiol 1992; 35: 101-114
178. Ambler GR, Johnston BM, Maxwell L, Gavin JB, Gluckman PD. Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I. Cardiovasc Res 1993; 27(7): 1368-1373 (Pubitemid 23250922)
179. Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993; 87: 1715-1721 (Pubitemid 23133116)
180. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95(2): 619-627
181. Cittadini A, Grossman JD, Napoli R, et al. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 1997; 29: 1109-1116 (Pubitemid 27149590)
182. Jin H, Yang R, Gillett N, Clark RG, Ko A, Paoni NF. Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J Cardiovasc Pharmacol 1995; 26(3): 420-425
183. Duerr RL, McKirnan MD, Gim RD, Clark RG, Chien KR, Ross J Jr. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation 1996; 93(12): 2188-2196 (Pubitemid 26187109)
184. Yang R, Bunting S, Gillet N, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995; 92: 262-267
185. Cittadini A, Isgaard J, Monti MG, et al. Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 2003; 41: 2154-2163 (Pubitemid 36733540)
186. Cittadini A, Strömer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 1996; 93(4): 800-809 (Pubitemid 26052467)
187. Grimm D, Cameron D, Griese DP, Riegger GAJ, Kromer E. Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. Cardiovas Res 1998; 40: 297-306. (Pubitemid 28506040)
188. Isgaard J, Kujacic V, Jennische E, et al. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 1997; 27(6): 517-525 (Pubitemid 27288363)
189. Ross J Jr, Hongo M. The role of hypertrophy and growth factors in heart failure. J Card Fail 1996; 2(4 Suppl): 121-128
190. Houck WV, Pan LC, Kribbs SB, et al. Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure. Circulation 1999; 100: 2003-2009 (Pubitemid 29529293)
191. Kinugawa S, Tsutsui H, Ide T, et al. Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovasc Res 1999; 43: 157-164 (Pubitemid 29322875)
192. Vetter U, Kupferschmid C, Lang D, Pentz S. Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes in vitro. Basic Res Cardiol 1988; 83: 647-654 (Pubitemid 19020710)
193. Freestone NS, Ribaric S, Mason WT. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol Cell Biochem 1996; 163-164: 223-229
194. 2+ handling and enhance cardiac performance in vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ Res 1996; 79: 227-236
195. 2+-dependent positive inotropic effects in failing human myocardium. Circ Res 2003; 92; 169-176
196. Gonzalez-Juanatey JR, Pineiro R, Iglesias MJ, et al. GH prevents apoptosis in cardiomyocytes cultured in vitro through a calcineurin-dependent mechanism. J Endocrinol 2004; 180: 325-335
197. Haunstetter A, Izumo S. Apoptosis. Basic mechanisms and implications for cardiovascular disease. Circ Res 1998; 82: 1111-1129
198. Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res 2000; 86: 1107-1113 (Pubitemid 30396034)
199. Baixeras E, Jeay S, Kelly PA, Postel-Vinay MC. The proliferative and antiapoptotic actions of growth hormone and insulin-like growth factor-1 are mediated through distinct signaling pathways in the Pro-B Ba/F3 cell line. Endocrinology 2001; 142: 2968-2977 (Pubitemid 32575534)
200. Jeay S, Sonenshein GE, Postel-Vinay MC, Baixeras E. Growth hormone prevents apoptosis through activation of nuclear factor-kB in interleukin-3-dependent Ba/F3 cell line. Mol Endocrinol 2000; 14: 650-661 (Pubitemid 32260509)
201. Jeay S, Sonenshein GE, Kelly PA, Postel-Vinay MC, Baixeras E. Growth hormone exerts antiapoptotic and proliferative effects through two different pathways involving nuclear factor-kB and phosphatidylinositol 3-kinase. Endocrinolgy 2001; 142: 147-156 (Pubitemid 32183676)
202. Cuneo RC, Wilmshurst P, Lowy C, McGauley G, Sonksen PH. Cardiac failure responding to growth hormone. Lancet 1989; 1: 838-839 (Pubitemid 19103147)
203. Frustaci A, Perrone GA, Gentiloni N, Russo MA. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol 1992; 97: 503-511
204. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-814 (Pubitemid 26099602)
205. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-1237 (Pubitemid 28181962)
206. Isgaard J, Bergh CH, Caidahl K, Lomsky M, Hjalmarson A, Bengtsson BA. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998; 19: 1704-1711 (Pubitemid 28524190)
207. Genth-Zotz S, Zotz R, Geil S, Voigtländer T, Meyer J, Darius H.Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 1999; 99: 18-21. (Pubitemid 29035951)
208. Spallarossa P, Rossettin P, Minuto F, et al. Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. Am J Cardiol 1999; 84: 430-433 (Pubitemid 29398664)
209. Perrot A, Ranke MB, Dietz R, Osterziel KJ. Growth hormone treatment in dilated cardiomyopathy. J Card Surg 2001; 16: 127-131 (Pubitemid 33097335)
210. Frustaci A, Gentiloni N, Russo MA. Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 335: 672-673
211. Jose VJ, Zechariah TU, George P, Jonathan V. Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study. Indian Heart J 1999; 51: 183-185 (Pubitemid 29288176)
212. Acevedo M, Corbalan R, Chamorro G, et al. Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol 2003; 87: 185-191 (Pubitemid 36135975)
213. Cittadini A, Comi IL, Longobardi S, et al. A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular distrophies. Eur Heart J 2003; 24: 664-672 (Pubitemid 36343200)
214. Smit JW, Janssen YJ, Lamb HJ, et al. Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass. J Clin Endocrinol Metab 2001; 86: 4638-4643
215. Adamopoulos S, Parissis JT, Georgiadis M, et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 2002; 144: 359-364 (Pubitemid 34879663)
216. Parissis JT, Adamopoulos S, Karatzas D, Paraskevaidis J, Livanis E, Kremastinos D. Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy. Eur J Cardiovasc Prev Rehabil 2005; 12: 164-168 (Pubitemid 40571530)
217. Adamopoulos S, Parissis JT, Paraskevaidis J, et al. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2003; 24: 2186-2196 (Pubitemid 37522671)
218. Fazio S, Palmieri EA, Affuso F, et al. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J Clin Endocrinol Metab 2007; 92: 4218-4223 (Pubitemid 350074734)
219. Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab 2007; 92: 180-185 (Pubitemid 46067528)